Huaibin Zhang
CEO, Founder @Waybio
Signup · Get unlimited contacts
WORK HISTORY
CEO, Founder @Waybio
Cambridge, MA, US
Founded WayBio to provide biotech teams with a domestic plasmid partner delivering secure, high-quality DNA solutions and collaborative scientist-to-scientist support. Built on expertise in automation, design frameworks, and advanced molecular methods, WayBio is designed to simplify plasmid work, accelerate research, and offer a frictionless Concept-to-Construct process for plasmid needs.Key Contributions• ACCELERATED R&D CYCLES: Established a U.S-based plasmid service platform that shortens synthesis and assembly timelines to about two weeks, compared with CRO averages of four to six weeks, while providing added support for design and verification phases.• PROTECTED INTELLECTUAL PROPERTY: Created a fully domestic supply chain that eliminates reliance on overseas vendors, safeguarding client IP and reducing geopolitical risks.• COLLABORATIVE SERVICE MODEL: Introduced a scientist-to-scientist approach with local Boston access, including same-day sample drop-off and rapid response capabilities.• DESIGN-POWERED INNOVATION: Implemented inventory-informed plasmid design methods to reduce redundant builds, cut engineering cycle times, and improve reproducibility.• STRATEGIC SCALABILITY: Positioned the company to expand beyond Boston, with applications in AI-driven protein engineering, cell and gene therapy, and RNA therapeutics.
EDUCATION
Tufts University
Postdoctorate Research Assistant, Microfluidics, microwell array, and ultra-sensitive Simoa technology
University of Waterloo
MS, Chemistry
Nankai University
BS, Chemistry
University of Illinois Urbana-Champaign
Resarch Assistant, Thesis: Bio-analytical Applications of Microfluidic Devices
University of Illinois Urbana-Champaign
PhD, Material Chemistry
SKILLS
ABOUT HUAIBIN ZHANG
CEO and Founder of WayBio, a Boston-based partner for biotech and biopharma teams seeking secure, high-quality plasmid DNA solutions delivered with precision, reliability, and direct scientist-to-scientist collaboration. WayBio is built around a frictionless Concept-to-Construct process for plasmid needs, combining advanced design methods with dependable in-house builds.WayBio Today Provides synthesis and assembly timelines of about two weeks compared with CRO averages of four to six weeks, with added design and verification support. Maintains a fully domestic supply chain to safeguard client IP and reduce geopolitical risks. Offers a scientist-to-scientist service model with local Boston access, including same-day sample drop-off. Applies inventory-informed design methods to reduce redundancy, improve reproducibility, and accelerate project timelines. Positions the company for scale in AI-driven protein engineering, cell and gene therapy, and RNA therapeutics.WayBio is also building a values-driven culture where teams are caring, humble, dependable, innovative, and purpose-driven, ensuring the company grows with integrity and impact.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.